Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor
Clinical trial NCT05276713 · UNKNOWN
Trial details
- NCT number
- NCT05276713
- Sponsor
- Beijing 302 Hospital
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2019-07-10
- Primary completion
- 2022-06-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.